Novolog (NVLG) AI Stock Analysis

• Market Cap: 655.96M
• Dividend Yield: 2.97%
• Average Volume (3M): 641.09K
• Price to Earnings (P/E): 32.7
• Beta (1Y): 0.68
• Revenue Growth: 22.79%
• EPS Growth: N/A
• Country: IL
• Employees: 936
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.80
• Shares Outstanding: 510,874,760
• 10 Day Avg. Volume: 285,794
• 30 Day Avg. Volume: 641,093
• PEG Ratio: -0.12
• Price to Book (P/B): 2.51
• Price to Sales (P/S): 0.46
• P/FCF Ratio: 9.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: 145.00 ▲(9.93% Upside)

Novolog's overall stock score reflects strong revenue growth but is tempered by declining profitability and cash flow issues. The technical analysis indicates bearish momentum, and the valuation suggests potential overvaluation despite a decent dividend yield. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Novolog's services, enhancing its market position and potential for long-term expansion.

Stable Balance Sheet

A stable balance sheet with moderate leverage suggests financial resilience, allowing Novolog to invest in growth and withstand economic fluctuations.

Strategic Partnerships

Long-term contracts through strategic partnerships provide a steady revenue stream, enhancing predictability and stability in financial performance.

Negative Factors

Declining Profitability Margins

Declining profitability margins indicate operational challenges, which could impact Novolog's ability to sustain earnings growth and reinvest in the business.

Cash Flow Challenges

Cash flow challenges may limit Novolog's ability to fund operations and growth initiatives, potentially affecting its financial flexibility and stability.

Declining Return on Equity

A declining return on equity suggests inefficiencies in generating profit from shareholders' investments, which could deter future investment.

Novolog Business Overview & Revenue Model

Company Description

Novolog (NVLG) is a logistics and supply chain management company specializing in providing efficient and innovative solutions for the pharmaceutical and healthcare sectors. The company offers a range of services including warehousing, distribution, and transportation, ensuring that critical healthcare products are delivered safely and on time. Novolog is committed to leveraging technology and expertise to optimize supply chain operations for its clients, thereby enhancing the availability and accessibility of essential medical supplies.

How the Company Makes Money

Novolog makes money primarily through service fees charged for its logistics and supply chain management services. The company's revenue model includes charging clients for warehousing and storage solutions, transportation and distribution services, and supply chain consultancy. Novolog may also generate income from value-added services such as temperature-controlled logistics and inventory management solutions. Strategic partnerships with pharmaceutical companies and healthcare providers play a crucial role in securing long-term contracts, providing a steady stream of revenue. Additionally, Novolog's investment in technology enables it to offer data-driven insights and analytics services, which can be an additional source of income.

Novolog Financial Statement Overview

Summary

Novolog demonstrates strong revenue growth but struggles with declining profitability margins and cash flow challenges. The balance sheet is stable with moderate leverage, but declining return on equity and cash flow metrics indicate areas for improvement.

Income Statement

Novolog has shown strong revenue growth, particularly in the TTM period with a 65.7% increase. However, profitability margins such as gross profit margin and net profit margin have declined over time, indicating pressure on profitability. The EBIT and EBITDA margins have also decreased, suggesting operational challenges.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.52, indicating a balanced approach to leverage. However, the return on equity has decreased in the TTM period, reflecting reduced profitability. The equity ratio remains stable, suggesting a solid capital structure.

Cash Flow

Free cash flow has significantly declined in the TTM period, with a negative growth rate, raising concerns about cash generation. The operating cash flow to net income ratio is low, indicating potential issues in converting earnings to cash. The free cash flow to net income ratio is negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.10B	2.02B	1.64B	1.51B	1.26B	1.13B
Gross Profit	156.10M	180.78M	173.76M	176.15M	148.96M	129.29M
EBITDA	129.76M	149.39M	130.14M	138.53M	115.92M	104.05M
Net Income	18.90M	39.54M	-42.00M	47.51M	42.32M	40.07M
Balance Sheet
Total Assets	3.06B	3.04B	2.79B	2.43B	2.29B	2.19B
Cash, Cash Equivalents and Short-Term Investments	218.49M	247.60M	232.94M	172.81M	238.71M	176.44M
Total Debt	190.42M	198.47M	215.18M	212.77M	166.81M	154.24M
Total Liabilities	2.67B	2.65B	2.39B	1.97B	1.86B	1.89B
Stockholders Equity	376.24M	368.38M	371.08M	436.00M	424.37M	294.69M
Cash Flow
Free Cash Flow	36.62M	99.78M	129.06M	63.16M	52.75M	32.87M
Operating Cash Flow	101.95M	158.52M	200.01M	132.65M	83.39M	58.48M
Investing Cash Flow	-57.02M	-50.55M	-72.60M	-124.95M	-69.07M	-28.61M
Financing Cash Flow	-64.33M	-94.59M	-67.71M	-72.96M	47.49M	-39.85M

Novolog Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 131.90
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Positive. The current price of 131.9 is above the 20-day moving average (MA) of 128.92, above the 50-day MA of 131.60, and below the 200-day MA of 144.56, indicating a neutral trend. The MACD of 0.68 indicates Negative momentum. The RSI at 52.73 is Neutral, neither overbought nor oversold. The STOCH value of 66.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:NVLG.

Novolog Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	72 Outperform	972.73M	43.13	10.95%	―	21.13%	251.25%
DANE	56 Neutral	2.75B	128.81	―	2.55%	5.94%	-52.48%
NVLG	56 Neutral	655.96M	32.67	―	2.97%	22.79%	―
SOFW	55 Neutral	1.11B	534.00	―	―	29.55%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%